Macrogen Inc (038290) Stock Price & News

038290:KOSDAQ

Macrogen Inc

₩12,300.00

+1.23%

(+150.00) 1D

Sep 4, 3:30:30 PM GMT+9 · KRW

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Generating top insights for 038290...

Open

₩12,150

High

₩12,400

Low

₩12,150

Mkt. cap

133.35B

Avg. vol.

37.90K

Volume

4.63K

Dividend

4.07%

Quarterly dividend

₩125

Ex-dividend date

Dec 27, 2024

P/E ratio

12.90

52-wk high

₩20,900

52-wk low

₩10,440

EPS

₩953

Shares outstanding

10.84M

No. of employees

487

Open

₩12,150

High

₩12,400

Low

₩12,150

Mkt. cap

133.35B

Avg. vol.

37.90K

Volume

4.63K

Dividend

4.07%

Quarterly dividend

₩125

Ex-dividend date

Dec 27, 2024

P/E ratio

12.90

52-wk high

₩20,900

52-wk low

₩10,440

EPS

₩953

Shares outstanding

10.84M

No. of employees

487

Related stocks

Soulbrain Holdings Co Ltd

₩43,100.00

+3.86%

005290

Dongjin Semichem Co Ltd

₩40,250.00

+1.26%

Profile

Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia

About Macrogen Inc

CEOSeo Jeong-seon

Employees487

FoundedJun 5, 1997

Headquarters-

SectorHealth care

Websitemacrogen.com

All values in KRW	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	49.06B	56.26B	45.29B	51.00B
Cost of goods sold	30.68B	35.05B	28.68B	32.54B
Cost of revenue	30.68B	35.05B	28.68B	32.54B
Research and development expenses	-	4.12B	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	17.10B	6.79B	16.97B	18.19B
Operating expense	17.27B	17.57B	17.12B	17.76B
Total operating expenses	47.95B	52.62B	45.80B	50.31B
Operating income	1.11B	3.64B	-508.86M	697.80M
Other non operating income	985.86M	2.18B	-239.63M	5.77B
EBT including unusual items	2.04B	3.49B	-796.15M	6.49B
EBT excluding unusual items	2.04B	2.30B	-748.48M	6.47B
Income tax expense	-46.70M	339.81M	30.55M	2.19B
Effective tax rate	-2.28%	9.75%	-3.84%	33.71%
Other operating expenses	-	1.37B	-	-
Net income	2.46B	3.38B	-437.22M	4.90B
Net profit margin	5.01%	6.00%	-0.97%	9.60%
Earnings per share	-	-	-	-
Interest and investment income	-	748.82M	-	-
Interest expense	-	-2.52B	-	-
Net interest expenses	-	-1.77B	-	-
Depreciation and amortization charges	-	3.66B	-	-
EBITDA	3.81B	7.98B	3.83B	5.04B
Gain or loss from assets sale	-	88.53M	-	-

Finance

Ask anything